Objective: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening infectious disease. Treatment requires multiple antimicrobial agents used for extended periods of time. The present study sought to evaluate the treatment success rate of bedaquiline-based regimens in MDR-TB patients. Methods: This was a systematic review and meta-analysis of studies published up to March 15, 2021. The pooled treatment success rates and 95% CIs were assessed with the fixed-effect model or the random-effects model. Values of p < 0.05 were considered significant for publication bias. Results: A total of 2,679 articles were retrieved by database searching. Of those, 29 met the inclusion criteria. Of those, 25 were observational studies (including a total of 3,536 patients) and 4 were experimental studies (including a total of 440 patients). The pooled treatment success rate was 74.7% (95% CI, 69.8-79.0) in the observational studies and 86.1% (95% CI, 76.8-92.1; p = 0.00; I2 = 75%) in the experimental studies. There was no evidence of publication bias (p > 0.05). Conclusions: In patients with MDR-TB receiving bedaquiline, culture conversion and treatment success rates are high even in cases of extensive resistance.

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis / Hatami, Hossein; Sotgiu, Giovanni; Bostanghadiri, Narjess; Abadi, Sahel Shafiee Dolat; Mesgarpour, Bita; Goudarzi, Hossein; Migliori, Giovanni Battista; Nasiri, Mohammad Javad. - In: JORNAL BRASILEIRO DE PNEUMOLOGIA. - ISSN 1806-3756. - 48:2(2022), p. e20210384. [10.36416/1806-3756/e20210384]

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis

Sotgiu, Giovanni;
2022-01-01

Abstract

Objective: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening infectious disease. Treatment requires multiple antimicrobial agents used for extended periods of time. The present study sought to evaluate the treatment success rate of bedaquiline-based regimens in MDR-TB patients. Methods: This was a systematic review and meta-analysis of studies published up to March 15, 2021. The pooled treatment success rates and 95% CIs were assessed with the fixed-effect model or the random-effects model. Values of p < 0.05 were considered significant for publication bias. Results: A total of 2,679 articles were retrieved by database searching. Of those, 29 met the inclusion criteria. Of those, 25 were observational studies (including a total of 3,536 patients) and 4 were experimental studies (including a total of 440 patients). The pooled treatment success rate was 74.7% (95% CI, 69.8-79.0) in the observational studies and 86.1% (95% CI, 76.8-92.1; p = 0.00; I2 = 75%) in the experimental studies. There was no evidence of publication bias (p > 0.05). Conclusions: In patients with MDR-TB receiving bedaquiline, culture conversion and treatment success rates are high even in cases of extensive resistance.
2022
Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis / Hatami, Hossein; Sotgiu, Giovanni; Bostanghadiri, Narjess; Abadi, Sahel Shafiee Dolat; Mesgarpour, Bita; Goudarzi, Hossein; Migliori, Giovanni Battista; Nasiri, Mohammad Javad. - In: JORNAL BRASILEIRO DE PNEUMOLOGIA. - ISSN 1806-3756. - 48:2(2022), p. e20210384. [10.36416/1806-3756/e20210384]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/292440
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? ND
social impact